Skip to content
value.today

Aptinyx Inc.

🇺🇸 Evanston, Illinois, USAPharmaceuticalsFounded 2015

Formerly Enarex, Inc., Eranix, Inc.

Total raised
$95 M
2 rounds on record
Latest round
$70 M
Dec 2017
First round on record
May 2016
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Aptinyx Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2017$70 MNo. 2$50 to $250 million

Aptinyx Inc.: Raise no. 2, Dec 2017

Investors in this round

63 investors had bought by the notice of Dec 21, 2017: 63 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Aptinyx Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$70 M of $70 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew D. Kidd · Executive Officer · Chief Commercial Officer
  • Ashish M. Khanna · Executive Officer · Chief Business Officer
  • Joseph R. Moskal · Executive Officer · Chief Scientific Officer
  • Norbert G. Riedel · Executive Officer, Director · President & Chief Executive Officer
  • Torsten M. Madsen · Executive Officer · Chief Medical Officer
  • Adam M. Koppel · Director
  • James P. Topper · Director
  • Liam P. Ratcliffe · Director
  • Patrick H. Enright · Director
  • Terry P. Gould · Director
  • Wilbur H. Gantz III · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ashish Khanna, Chief Business Officer. Source: SEC Form D, newest notice filed Dec 21, 2017. Read the notice at the SEC.

equitySEC
May 2016$25 MNo. 1$10 to $50 million

Aptinyx Inc.: Raise no. 1, May 2016

Investors in this round

48 investors had bought by the notice of May 19, 2016: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 17 investors are named for Aptinyx Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $65 M offered; $40 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ashish G. Khanna · Executive Officer · Secretary & Chief Business Officer
  • Joseph R. Moskal · Executive Officer · Chief Scientific Officer
  • Norbert G. Riedel · Executive Officer, Director · Chief Executive Officer
  • Torsten M. Madsen · Executive Officer · Chief Marketing Officer
  • James N. Topper · Director
  • Liam P. Ratcliffe · Director
  • Patrick G. Enright · Director
  • Terry P. Gould · Director
  • Wilbur H. Gantz III · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ashish Khanna, Secretary & Chief Business Officer. Source: SEC Form D, newest notice filed May 19, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aptinyx Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2017).

    SEC Form D · Dec 2017

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2017

That is all the official record says: Aptinyx Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

17 named in official filings. Open an investor to see everything it has backed.

Investors in Aptinyx Inc.
InvestorKindAmountRoundRoleSource
Adams Street Partners LLCFund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Andrew KiddPersonnot statednot statedHeld Series B preferred stock (Form 3, 2018)SEC Form 3
Ashish KhannaPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock (Form 3, 2018)SEC Form 3
David HouckPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock (Form 3, 2018)SEC Form 3
FHM Life Sciences VIII, L.L.C.Othernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
FHM Life Sciences VIII, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Frazier Life Sciences VIII, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Joseph R. MoskalPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock (Form 3, 2018)SEC Form 3
Longitude Capital Partners II, LLCFund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Longitude Venture Partners II, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
New Leaf Biopharma Opportunities I, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
New Leaf BPO Associates I, L.P.Fund or asset managernot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
New Leaf Venture Associates III, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
New Leaf Venture Management III, L.L.C.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
New Leaf Ventures III, L.P.Venture capitalnot statednot statedHeld Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Norbert G. RiedelPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock, director (Form 3, 2018)SEC Form 3
Torsten M. MadsenPersonnot statednot statedHeld Series A-1, A-2 and B preferred stock (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 63 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aptinyx Inc.
NameRoleNamed in
Andrew D. KiddChief Commercial OfficerDec 2017
Ashish M. KhannaChief Business OfficerDec 2017
Joseph R. MoskalChief Scientific OfficerDec 2017
Norbert G. RiedelPresident & Chief Executive OfficerDec 2017
Torsten M. MadsenChief Medical OfficerDec 2017
Ashish G. KhannaSecretary & Chief Business OfficerMay 2016
Adam M. KoppelDirectorDec 2017
James P. TopperDirectorDec 2017
Liam P. RatcliffeDirectorDec 2017
Norbert G. RiedelPresident & Chief Executive OfficerDec 2017
Patrick H. EnrightDirectorDec 2017
Terry P. GouldDirectorDec 2017
Wilbur H. Gantz IIIDirectorDec 2017
James N. TopperDirectorMay 2016
Patrick G. EnrightDirectorMay 2016